Adefovir dipivoxil (Synonyms: GS 0840)

Name: Adefovir dipivoxil
Brand: MedChemExpress
SKU: HY-B0255
Rating: 5.0 (2 reviews)

製品番号: HY-B0255 純度: 99.03%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the ATR signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Adefovir dipivoxil 構造式

CAS 番号 : 142340-99-6

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solid
50 mg	$55	在庫あり	Estimated Time of Arrival: December 31
100 mg	$77	在庫あり	Estimated Time of Arrival: December 31
500 mg	$150	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Other Forms of Adefovir dipivoxil:

Adefovir dipivoxil (Standard) お問い合わせ

顧客検証

HSV アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

HSV-1 HSV-2 HSV

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

ATM/ATR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ATM ATR TRRAP

CDK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	0.74 μM Compound: 15, Bis(POM)-PMEA	Cytotoxicity against CEM/O cells Cytotoxicity against CEM/O cells	[PMID: 16335932]
CCRF-CEM	CC₅₀	1.6 μM Compound: 11, Bis-POM-PMEA	Cytotoxicity against mock-infected human CEM cells assessed as growth inhibition Cytotoxicity against mock-infected human CEM cells assessed as growth inhibition	[PMID: 23603046]
CCRF-CEM	EC₅₀	0.045 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
CCRF-CEM	EC₅₀	0.062 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
CEM-SS	CC₅₀	4.4 μM Compound: 3	Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1. Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.	[PMID: 8960556]
CEM-SS	EC₅₀	0.04 μM Compound: 3	Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1. Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.	[PMID: 8960556]
HEK293	IC₅₀	13.5 μM Compound: ADV	Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method	[PMID: 31301948]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	4 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HepG2 2.2.15	CC₅₀	>400 μM Compound: ADV	Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay	[PMID: 27458783]
HepG2 2.2.15	CC₅₀	438.92 μM Compound: ADV	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay	[PMID: 31301948]
HepG2 2.2.15	CC₅₀	471.1 μM Compound: 1	Cytotoxicity against human HepG2(2.2.15) cells infected with HBV DNA Cytotoxicity against human HepG2(2.2.15) cells infected with HBV DNA	[PMID: 22305613]
HepG2 2.2.15	CC₅₀	555 μM Compound: 2	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 19889538]
HepG2 2.2.15	EC₅₀	0.96 μM Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis	[PMID: 22305613]
HepG2 2.2.15	EC₅₀	1.5 μM Compound: ADV	Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	1.8 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	7.5 μM Compound: ADV	Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	IC₅₀	0.33 μM Compound: 2	Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR	[PMID: 19889538]
HepG2 2.2.15	IC₅₀	0.48 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.48 μmol Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.58 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.58 μmol Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis	10.1007/s00044-011-9616-2
HK-2	CC₅₀	488.05 μM Compound: 1	Cytotoxicity against human HK2 cells by MTT assay Cytotoxicity against human HK2 cells by MTT assay	[PMID: 22305613]
Huh-7	CC₅₀	>25 μM Compound: 11, Bis-POM-PMEA	Cytotoxicity against human HuH7 cells assessed as reduction of cell density Cytotoxicity against human HuH7 cells assessed as reduction of cell density	[PMID: 23603046]
Huh-7	CC₅₀	365 μM Compound: adefovir, adefovir dipivoxil, ADV	Effect on cell viability in human Huh7 cells Effect on cell viability in human Huh7 cells	[PMID: 17371827]
Huh-7	EC₅₀	0.83 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis	[PMID: 23603046]
Huh-7	EC₅₀	1.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	13 μM Compound: adefovir, adefovir dipivoxil, ADV	Inhibition of wild type HBV replication in Huh7 cells Inhibition of wild type HBV replication in Huh7 cells	[PMID: 17371827]
Huh-7	EC₅₀	14 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2 μM Compound: Adefovir dipivoxil	Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.4 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.6 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
MRC5	CC₅₀	15.7 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.	[PMID: 8960556]
MRC5	EC₅₀	0.91 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-2. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-2.	[PMID: 8960556]
MRC5	EC₅₀	1.23 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.	[PMID: 8960556]
MT4	CC₅₀	0.74 μM Compound: 3	Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1. Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.	[PMID: 8960556]
MT4	EC₅₀	0.08 μM Compound: 3	Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1. Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.	[PMID: 8960556]
Vero	CC₅₀	22.56 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-1. Compound was tested for antiviral activity against the Vero cells infected with HSV-1.	[PMID: 8960556]
Vero	EC₅₀	0.87 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-1. Compound was tested for antiviral activity against the Vero cells infected with HSV-1.	[PMID: 8960556]
Vero	EC₅₀	1.15 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-2 Compound was tested for antiviral activity against the Vero cells infected with HSV-2	[PMID: 8960556]
Vero	IC₅₀	0.6 μM Compound: 10a	Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro	[PMID: 8021925]
WI-38	CC₅₀	3.1 μM Compound: PMEA dipivoxil	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	0.7 μM Compound: PMEA dipivoxil	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

体外実験

Adefovir dipivoxil (0.03-30 μM; 6 days) significantly inhibits the proliferation of H1975, A549 and PC9 cells, with more pronounced inhibition when co-treated with VE822^[1].
Adefovir dipivoxil (1 μM; 3 days) exhibits increased basolateral-to-apical transport and an elevated efflux ratio in Caco-2 cells treated with 1,25(OH)₂D₃^[2].
Adefovir dipivoxil (24 h) can effectively inhibit PRV proliferation in PK-15 cells, with an IC₅₀ of 92.39 nM^[4].
Adefovir dipivoxil (1-10 μM) sensitizes colon cancer cells (HCT116-CDK1 and HT29-CDK1 cells) to Vemurafenib (HY-12057) by disrupting KCTD12-CDK1 interaction^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	H1975
Concentration:	0.1, 1, 3, 10, 30 μM
Incubation Time:	24 h
Result:	Activated the ATR signaling pathway. Resulted in changes in the levels of cell cycle protein F, phosphorylated CDK2, RRM2, phosphorylated RPA, γH2AX, and other related proteins as a result of co-treatment with VE822.

体内実験

Adefovir dipivoxil (5 mg/kg; i.p.; once a day, 5 days) can potently protect mice against lethal PRV infection, as shown by reduced pathological lesions, lower viral particles in major organs, and increased survival rate^[4].
Adefovir dipivoxil (10-50 mg/kg; p.o.; every other day) inhibits the growth of colon cancer cell-derived tumor xenografts in BALB/c nude mice^[5].
Adefovir dipivoxil (100 mg/kg/day; p.o.; twice daily; 10 days) reduces viral load in the liver and serum in transgenic mice expressing hepatitis B virus (HBV)^[6].
Adefovir dipivoxil (250 mg prodrug per dog for suspension; p.o.; single dose) shows oral bioavailability of 35.0% (suspension) in beagle dogs^[7].
Adefovir dipivoxil (30 mg/kg; every other day; 21 days) causes a marked reduction of duck HBV (DHBV) DNA in serum in congenitally HBV-infected ducklings^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice expressing HBV^[6]
Dosage:	100 mg/kg/day
Administration:	Oral gavage, twice daily for 10 days; once daily for 10-21 days
Result:	Reduced liver HBV DNA to near the levels of detection (0.02 pg viral DNA/g cellular DNA) at 100 mg/kg/day twice daily. Had significant antiviral effects on serum HBV DNA on days 4, 7, 10, and 21 when administered once daily at a dose of 100 mg/kg/day. Was effective in significantly reducing liver HBV DNA with once-daily treatment at doses as low as 1.0 mg/kg/day. Had no significant effect on core antigen (HBcAg) in the liver or pre-core antigen (HBeAg) in the serum, and did not significantly reduce liver HBV RNA.

臨床実験

分子量

501.47

分子式

C₂₀H₃₂N₅O₈P

CAS 番号

142340-99-6

Appearance

Solid

Color

White to off-white

SMILES

NC1=C2N=CN(CCOCP(OCOC(C(C)(C)C)=O)(OCOC(C(C)(C)C)=O)=O)C2=NC=N1

Structure Classification

Others

Initial Source

Endogenous metabolite

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (199.41 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 0.67 mg/mL (1.34 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9941 mL	9.9707 mL	19.9414 mL
5 mM	0.3988 mL	1.9941 mL	3.9883 mL
10 mM	0.1994 mL	0.9971 mL	1.9941 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.03%

Select Batch:

データシート (284 KB) SDS (393 KB)

COA (252 KB) LCMS (94 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Patel A, et al. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. Int J Cancer. 2020 Sep 1;147(5):1474-1484. [Content Brief]

[2]. Maeng HJ, et al. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. Eur J Pharm Sci. 2012 Jun 14;46(3):149-66. [Content Brief]

[3]. Annaert P, et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J Pharm Sci. 2000 Aug;89(8):1054-62. [Content Brief]

[4]. Wang G, et al. Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo. Antiviral Res. 2021 Feb;186:105014. [Content Brief]

[5]. Yang J, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett. 2019 Jun 1;451:79-91. [Content Brief]

[6]. Julander JG, et al. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002 Jul;55(1):27-40. [Content Brief]

[7]. Cundy KC, et al. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci. 1997 Dec;86(12):1334-8. [Content Brief]

[8]. Qaqish RB, et al. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther. 2003 Dec;25(12):3084-99. [Content Brief]

[9]. Buti M, et al. Adefovir dipivoxil. Drugs Today (Barc). 2003;39(2):127-135. [Content Brief]

[10]. Mark N Prichard, et al. Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord. 2005 Mar;5(1):17-28. [Content Brief]

[11]. Noble S, et al. Adefovir dipivoxil. Drugs. 1999;58(3):479-489. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.9941 mL	9.9707 mL	19.9414 mL	49.8534 mL
DMSO	5 mM	0.3988 mL	1.9941 mL	3.9883 mL	9.9707 mL
	10 mM	0.1994 mL	0.9971 mL	1.9941 mL	4.9853 mL
	15 mM	0.1329 mL	0.6647 mL	1.3294 mL	3.3236 mL
	20 mM	0.0997 mL	0.4985 mL	0.9971 mL	2.4927 mL
	25 mM	0.0798 mL	0.3988 mL	0.7977 mL	1.9941 mL
	30 mM	0.0665 mL	0.3324 mL	0.6647 mL	1.6618 mL
	40 mM	0.0499 mL	0.2493 mL	0.4985 mL	1.2463 mL
	50 mM	0.0399 mL	0.1994 mL	0.3988 mL	0.9971 mL
	60 mM	0.0332 mL	0.1662 mL	0.3324 mL	0.8309 mL
	80 mM	0.0249 mL	0.1246 mL	0.2493 mL	0.6232 mL
	100 mM	0.0199 mL	0.0997 mL	0.1994 mL	0.4985 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Adefovir dipivoxil Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Adefovir dipivoxil (Synonyms: GS 0840)

カスタマーレビュー

Other Forms of Adefovir dipivoxil:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

HSV アイソフォーム固有の製品をすべて表示:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

ATM/ATR アイソフォーム固有の製品をすべて表示:

CDK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Adefovir dipivoxil Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Adefovir dipivoxil (Synonyms: GS 0840)

カスタマーレビュー

Other Forms of Adefovir dipivoxil:

Adefovir dipivoxil 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

HSV アイソフォーム固有の製品をすべて表示:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

ATM/ATR アイソフォーム固有の製品をすべて表示:

CDK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Adefovir dipivoxil 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Adefovir dipivoxil Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report